Sign in
Taking people in South KoreaNo phase

Studies biomarkers that may predict Alzheimer's in people with inherited mutations

Looks for signs that may predict Alzheimer's disease in adults carrying a gene mutation.

Key facts

Who runs it
Washington University School of Medicine
Where
Seoul, South KoreaSee the siteAlso in 12 other countries, 25 sites
Trial code
Registry title
Dominantly Inherited Alzheimer Network (DIAN)
Status
Recruiting
People taking part
700 people, planned
Started
Jan 2009
Expected to end
Sept 2031
Type of study
Observational, 2 groups
Record updated
5 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults whose parent has Alzheimer's disease caused by a known inherited gene mutation. Most people recruited have no memory problems yet.

Age
18 years or older
Sex
Women and men can join
Disease stage
No memory problems, or very mild or mild memory problems (CDR score 0 to 1.0). Most new people are adult children with no symptoms, more than 15 years younger than the expected age when symptoms start. People with moderate memory problems can join only with approval from the DIAN Coordinating Center.
Biomarker or test result
Is the child of a parent with a known Alzheimer's mutation for ADAD (a dominantly inherited form of Alzheimer's disease). The parent's mutation was shown by symptoms or by a test.

Main reasons for not taking part

  • Younger than 18
  • An illness, medical or mental, that would get in the way of the visits
  • Needs nursing home level care
  • Has no one who can act as an informant for the study

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Written informed consent obtained from participant and collateral source prior to any study-related procedures
  • Aged 18 (inclusive) or older and the child of an affected individual (clinically or by testing) in a pedigree with a known mutation for ADAD
  • Cognitively normal to very mild or mild cognitive impairment (CDR score range 0-1.0). Primary enrollment will focus on the recruitment of asymptomatic adult children who are more than 15 years younger than the estimated age of symptom onset. Enrollment of new participants with moderate cognitive impairment is allowed with the prior approval of the DIAN Coordinating Center
  • Has two persons who are not their full-blooded siblings who can serve as collateral sources for the study
  • Fluent in a language approved by the DIAN Coordinating Center at about the 6th grade level (international equivalent) or above

Who cannot take part

  • Medical or psychiatric illness that would interfere in completing initial and follow-up visits
  • Under age 18
  • Requires nursing home level care
  • Has no one who can serve as a study informant

Where in South Korea

Also in 12 other countries, 25 sites

  • Asan Medical CenterSeoul, South KoreaContact: Jee Hoon Roh, MD, PhDTaking people

About the trial

What the trial wants to find out

The purpose of this study is to identify potential biomarkers that may predict the development of Alzheimer's disease in people who carry an Alzheimer's mutation.

The 2 groups in the trial

  • 1

    Mutation Positive

  • 2

    Mutation Negative

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Dominantly Inherited Alzheimer Network (DIAN)
Plain-language title
Studies biomarkers that may predict Alzheimer's in people with inherited mutationsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Publications
Record updated
5 October 2026